JP2017160178A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160178A5
JP2017160178A5 JP2016108649A JP2016108649A JP2017160178A5 JP 2017160178 A5 JP2017160178 A5 JP 2017160178A5 JP 2016108649 A JP2016108649 A JP 2016108649A JP 2016108649 A JP2016108649 A JP 2016108649A JP 2017160178 A5 JP2017160178 A5 JP 2017160178A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weeks
antagonist
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016108649A
Other languages
English (en)
Japanese (ja)
Other versions
JP6654967B2 (ja
JP2017160178A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160178A publication Critical patent/JP2017160178A/ja
Publication of JP2017160178A5 publication Critical patent/JP2017160178A5/ja
Application granted granted Critical
Publication of JP6654967B2 publication Critical patent/JP6654967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016108649A 2015-04-14 2016-05-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物 Active JP6654967B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2015082699 2015-04-14
JP2016041641 2016-03-04
JP2016041641 2016-03-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016522817A Division JP5954916B1 (ja) 2015-04-14 2016-04-13 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020015220A Division JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Publications (3)

Publication Number Publication Date
JP2017160178A JP2017160178A (ja) 2017-09-14
JP2017160178A5 true JP2017160178A5 (OSRAM) 2019-05-23
JP6654967B2 JP6654967B2 (ja) 2020-02-26

Family

ID=57126544

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016108649A Active JP6654967B2 (ja) 2015-04-14 2016-05-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2020015220A Active JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021066854A Withdrawn JP2021105051A (ja) 2015-04-14 2021-04-12 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021149027A Pending JP2021193124A (ja) 2015-04-14 2021-09-14 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2023123359A Pending JP2023134842A (ja) 2015-04-14 2023-07-28 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2025086586A Pending JP2025122131A (ja) 2015-04-14 2025-05-23 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2020015220A Active JP6887212B2 (ja) 2015-04-14 2020-01-31 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021066854A Withdrawn JP2021105051A (ja) 2015-04-14 2021-04-12 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2021149027A Pending JP2021193124A (ja) 2015-04-14 2021-09-14 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2023123359A Pending JP2023134842A (ja) 2015-04-14 2023-07-28 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
JP2025086586A Pending JP2025122131A (ja) 2015-04-14 2025-05-23 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Country Status (14)

Country Link
US (2) US10544227B2 (OSRAM)
EP (1) EP3284480B1 (OSRAM)
JP (6) JP6654967B2 (OSRAM)
KR (1) KR20170134748A (OSRAM)
CN (1) CN107614016B (OSRAM)
BR (1) BR112017022101A2 (OSRAM)
CA (1) CA2980992C (OSRAM)
MA (1) MA43918A (OSRAM)
MX (2) MX390570B (OSRAM)
NO (1) NO2025047I1 (OSRAM)
PT (1) PT3284480T (OSRAM)
RU (1) RU2749512C2 (OSRAM)
TW (4) TW202515609A (OSRAM)
WO (1) WO2016167263A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
ES3036076T3 (en) 2015-04-14 2025-09-12 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2017126488A1 (ja) * 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
SG11202007558YA (en) * 2018-02-09 2020-09-29 Nestle Skin Health Sa Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
KR102780168B1 (ko) 2018-05-21 2025-03-11 추가이 세이야쿠 가부시키가이샤 유리 용기에 봉입된 동결건조 제제
MX2021008144A (es) * 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
CN114555121A (zh) * 2019-08-29 2022-05-27 金德雷德生物科学股份有限公司 兽用抗il31抗体
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
JPWO2022113316A1 (OSRAM) * 2020-11-30 2022-06-02
TW202304510A (zh) * 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (OSRAM) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (OSRAM) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
JPH08503617A (ja) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド L−セレクチンに反応性のヒト化抗体
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
CN101070344A (zh) 1998-04-30 2007-11-14 泰诺士公司 G-csf受体兴奋剂抗体及其筛选方法
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU759689B2 (en) 1998-06-24 2003-04-17 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
JP2004501628A (ja) 2000-06-26 2004-01-22 ザイモジェネティクス,インコーポレイティド サイトカイン受容体zcytor17
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
KR100881900B1 (ko) 2001-04-05 2009-02-04 가부시키가이샤 멘에키세이부츠 켄큐죠 항-오스테오폰틴 항체 및 그 용도
JP4511349B2 (ja) 2002-01-18 2010-07-28 ザイモジェネティクス,インコーポレイティド サイトカイン受容体zcytor17マルチマー
EP1476541B1 (en) 2002-01-18 2008-07-16 ZymoGenetics, Inc. Cytokine (zcytor17 ligand)
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
BR0304660A (pt) 2002-05-01 2005-06-07 Schering Ag Anticorpos direcionados a fator de tecido como anticoagulantes
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
EP1605974B1 (en) 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
MXPA05010134A (es) 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
EP1713325A2 (en) 2004-02-12 2006-10-25 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006088855A1 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス, インコーポレイテッド Il−31モノクローナル抗体とその使用法
MX2008008831A (es) 2006-01-10 2009-03-04 Zymogenetics Inc Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
NZ599035A (en) 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
PE20080333A1 (es) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
WO2007147122A2 (en) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Claudin−4抗体
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
JP2010531340A (ja) 2007-07-10 2010-09-24 エフ.ホフマン−ラ ロシュ アーゲー 新規処方物
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
MY162546A (en) 2007-12-05 2017-06-15 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
MX337081B (es) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항nr10 항체 및 그의 이용
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
SI2892927T1 (sl) 2012-09-07 2018-10-30 Regeneron Pharmaceuticals,Inc Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP5650871B1 (ja) * 2013-06-28 2015-01-07 中外製薬株式会社 そう痒を伴う疾患に罹患した患者のil−31アンタゴニストによる治療に対する応答を予測する方法
WO2016167263A1 (ja) * 2015-04-14 2016-10-20 中外製薬株式会社 Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US10493149B2 (en) 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation
KR102780168B1 (ko) 2018-05-21 2025-03-11 추가이 세이야쿠 가부시키가이샤 유리 용기에 봉입된 동결건조 제제
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
JP6799831B1 (ja) 2020-09-01 2020-12-16 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Similar Documents

Publication Publication Date Title
JP2017160178A5 (OSRAM)
RU2017138551A (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
JP2017160208A5 (OSRAM)
JP2018184417A5 (OSRAM)
JP2015529225A5 (OSRAM)
JP2015525798A5 (OSRAM)
JP2016528247A5 (OSRAM)
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2006522830A5 (OSRAM)
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
JP2014114288A5 (OSRAM)
JP2017503820A5 (OSRAM)
JP2015007098A5 (OSRAM)
JP2016530280A5 (OSRAM)
JP2015534579A5 (OSRAM)
JP2014533279A5 (OSRAM)
JP2016185995A5 (OSRAM)
JP2018506550A5 (OSRAM)
JP2022160685A5 (OSRAM)
JP2020502219A5 (OSRAM)
JP2018530578A5 (OSRAM)
JP2020535149A5 (OSRAM)
JP2022041802A5 (OSRAM)
JP2018529661A5 (OSRAM)
JP2019532970A5 (OSRAM)